Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.
|Number of pages||10|
|Journal||Digestive Diseases and Sciences|
|State||Published - Aug 2014|
Bibliographical noteFunding Information:
Acknowledgments The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
- Epidermal growth factor
- Hepatocellular carcinoma
- Liver cancer stem cells
ASJC Scopus subject areas